Azithromycin, doxycyline, MGD, blepharitis, dry eyes
Conditions
Interventions
Two groups:Azithromycin 1.5% Topical
Doxycyline 100mg Oral
Multivitamin Daily 1 Plus 1 tablet Oral Three months
(to be continued):Group 1 (control treatment): topical azithromycin to both eyes, twice daily for 3 days, then once daily for 25 days
and oral multivitamin (Daily 1 Plus) 1 tablet a day concurrently for 28 days as placebo
(to be continured):Group 2 (study treatment): topical azithromycin as above, and oral doxycycline 100mg (1 tablet) a day concurrently for 28 days.
Sponsors
Hong Kong Medical Supplies Ltd (Thea Laboratories)
Eligibility
Sex/Gender
Male
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Symptomatic meibomian gland dysfunction not responding to warm compresses, lid massage, and lubricants; 2. Older than 12 year old; 3. Able to give informed consent; 4. Able to comply with treatment and follow-up schedule.
Exclusion criteria
Exclusion criteria: 1. On treatment for MGD or dry eye syndrome other than warm compresses, lid massage and lubricants in the past 3 months; 2. Schirmer's test without anaesthesia =100 in both eyes; 3. Known allergy to tetracycline or macrolide; 4. Pregnant or breast feeding women; 5. Women planning pregnancy; 6. Hepatic impairment or on hepatotoxic drugs; 7. Severe renal impairment; 8. Ocular condition that causes similar symptoms and signs as MGD, including structural lid abnormalities, lagothalmos, conjunctivochalasis, contact lens wear, thyroid eye disease; 9. On systemic medications that may contribute to dry eye without being on a stable dose in the past 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in symptom frequency score based on self-administered OSDI questionnaire at month 1; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in symptom frequency score based on self-administered OSDI questionnaire at month 3;Improvement in symptom severity score based on self-administered SPEED questionnaire;Clinical grading of MGD based on conjunctival injection, lid margin redness, ocular surface staining, meibomian gland expressability, number of glands plugged and quality of meibum13;Best- corrected visual acuity;Lipid layer thickness measurement by LipiView interferometer (TearScience Inc., Morrisville, NC, USA) The LipiView interferometer (TearScience Inc., Morrisville, NC, USA) measures interferometric color units (ICU), where 1 ICU approximately reflects 1 nm of the lipid layer thickness.;18 A LipiView image of the tear film can be captured during a non-invasive in-office exam that takes about 5 minutes.;The tear film can be seen as an array of colors called specular observations that are relected when the subject rest his head on the chin-rest and a controlled light source is directed towards the front surface of the eye.;Non-invasive tear break-up time, infrared meibography, tear film assessment and R-scan (bulbar conjunctival redness evaluation) with OCULUS Keratograph 5M (Oculus, Wetzlar, Germany) OCULUS Keratograph 5M (Oculus, Wetzlar, Germany) uses white or infrared illumination to assess the tear film and tear break-up time;infrared camera for meibomian gland imaging; and color camera for conjunctival blood vessel imaging.;All measurements will be non-invasive. Subjects will be instructed to rest his head on the chin- rest during imaging, which takes about 5 minutes.;Tear analysis (10 patients in each arm): osmolarity, cytokines, matrix metalloproteinases;Side effects noted during treatment;Compliance to treatment; | — |
Countries
China
Contacts
Public ContactDr. Vanissa Wing-see CHOW
Outcome results
None listed